LT3880186T - Pd-1 inhibitorių skyrimas į pažeidimo vietą odos vėžiui gydyti - Google Patents

Pd-1 inhibitorių skyrimas į pažeidimo vietą odos vėžiui gydyti

Info

Publication number
LT3880186T
LT3880186T LTEPPCT/US2019/061212T LTUS2019061212T LT3880186T LT 3880186 T LT3880186 T LT 3880186T LT US2019061212 T LTUS2019061212 T LT US2019061212T LT 3880186 T LT3880186 T LT 3880186T
Authority
LT
Lithuania
Prior art keywords
inhibitors
treatment
skin cancer
site administration
administration
Prior art date
Application number
LTEPPCT/US2019/061212T
Other languages
English (en)
Lithuanian (lt)
Inventor
Matthew G. Fury
Israel Lowy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3880186T publication Critical patent/LT3880186T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
LTEPPCT/US2019/061212T 2018-11-14 2019-11-13 Pd-1 inhibitorių skyrimas į pažeidimo vietą odos vėžiui gydyti LT3880186T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767218P 2018-11-14 2018-11-14
PCT/US2019/061212 WO2020102375A1 (en) 2018-11-14 2019-11-13 Intralesional administration of pd-1 inhibitors for treating skin cancer

Publications (1)

Publication Number Publication Date
LT3880186T true LT3880186T (lt) 2024-06-10

Family

ID=68841191

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/061212T LT3880186T (lt) 2018-11-14 2019-11-13 Pd-1 inhibitorių skyrimas į pažeidimo vietą odos vėžiui gydyti

Country Status (16)

Country Link
US (2) US12473364B2 (cg-RX-API-DMAC7.html)
EP (2) EP3880186B1 (cg-RX-API-DMAC7.html)
JP (2) JP7513604B2 (cg-RX-API-DMAC7.html)
CN (1) CN113038939A (cg-RX-API-DMAC7.html)
DK (1) DK3880186T3 (cg-RX-API-DMAC7.html)
ES (1) ES2980363T3 (cg-RX-API-DMAC7.html)
FI (1) FI3880186T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240825T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067601T2 (cg-RX-API-DMAC7.html)
LT (1) LT3880186T (cg-RX-API-DMAC7.html)
PL (1) PL3880186T3 (cg-RX-API-DMAC7.html)
PT (1) PT3880186T (cg-RX-API-DMAC7.html)
RS (1) RS65627B1 (cg-RX-API-DMAC7.html)
SI (1) SI3880186T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400252T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020102375A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
CN116134155A (zh) * 2020-08-26 2023-05-16 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症的方法
JP2024511106A (ja) * 2021-03-23 2024-03-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Pd-1阻害剤を投与することにより免疫抑制または免疫不全患者におけるがんを処置する方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
CA2698419C (en) 2007-09-07 2019-11-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
HUE037659T2 (hu) 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
ES2742379T3 (es) 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
JP6295998B2 (ja) 2015-05-12 2018-03-20 株式会社デンソー 内燃機関の再始動制御装置
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
IL261998B2 (en) 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CN117442719A (zh) 2017-02-21 2024-01-26 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
US10166290B2 (en) 2017-02-24 2019-01-01 Max H. Cohen Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof

Also Published As

Publication number Publication date
US20260042841A1 (en) 2026-02-12
PT3880186T (pt) 2024-05-28
SMT202400252T1 (it) 2024-07-09
EP4382168A2 (en) 2024-06-12
HUE067601T2 (hu) 2024-10-28
WO2020102375A1 (en) 2020-05-22
JP2024123216A (ja) 2024-09-10
PL3880186T3 (pl) 2024-07-22
JP7513604B2 (ja) 2024-07-09
JP7904269B2 (ja) 2026-08-12
US20210388091A1 (en) 2021-12-16
JP2022513029A (ja) 2022-02-07
HRP20240825T1 (hr) 2024-09-27
EP3880186B1 (en) 2024-04-03
DK3880186T3 (da) 2024-06-03
EP3880186A1 (en) 2021-09-22
FI3880186T3 (fi) 2024-05-30
RS65627B1 (sr) 2024-07-31
SI3880186T1 (sl) 2024-07-31
EP4382168A3 (en) 2024-08-28
US12473364B2 (en) 2025-11-18
CN113038939A (zh) 2021-06-25
ES2980363T3 (es) 2024-10-01

Similar Documents

Publication Publication Date Title
SI3455258T1 (sl) Postopki za zdravljenje kožnega raka z dajanjem zaviralca PD-1
IL268676A (en) Inhibition of smarca2 for treatment of cancer
EP3618829A4 (en) QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER ASSOCIATED DISORDERS
PT3902803T (pt) Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro
IL282776A (en) Plasmid constructs for treating cancer and methods of use
IL269150A (en) Compositions and methods for treating cancer
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
IL268814A (en) Compositions and methods for treatment of cancer
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
PL3426250T3 (pl) Leczenie pacjenta lekiem będącym substratem CYP3A4 przeciwwskazanym do jednoczesnego podawania z silnym inhibitorem CYP3A4
IL263224A (en) Methods and compositions for treating cancers
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
IL254133A0 (en) Combination of a pd-1 antagonist and eribulin for treating cancer
IL268872A (en) Methods and compositions for treating cancers using antisense
IL269157A (en) Compositions and methods for treating cancer
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
IL281244A (en) Combination therapy for the treatment of liver disease
IL285050A (en) Administering PD-1 inhibitors for the treatment of skin cancer
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
DK4225297T3 (da) Kombinationsbehandling til behandling af cancer
IL274198A (en) Use of Nox inhibitors to treat cancer
IT201900016760A1 (it) Dispositivo per il trattamento radioterapico di malati oncologici
DK3880186T3 (da) Intralæsional administration af pd-1-hæmmere til behandling af hudcancer
IL261384A (en) Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer